Profund Advisors LLC cut its holdings in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH – Free Report) by 19.9% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 3,364 shares of the medical equipment provider’s stock after selling 836 shares during the period. Profund Advisors LLC’s holdings in Lantheus were worth $270,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Janney Montgomery Scott LLC boosted its position in Lantheus by 6.2% during the 4th quarter. Janney Montgomery Scott LLC now owns 8,005 shares of the medical equipment provider’s stock worth $497,000 after acquiring an additional 467 shares during the period. Norges Bank bought a new stake in shares of Lantheus during the 4th quarter worth about $29,956,000. PNC Financial Services Group Inc. lifted its stake in shares of Lantheus by 14.3% in the 4th quarter. PNC Financial Services Group Inc. now owns 9,613 shares of the medical equipment provider’s stock worth $596,000 after acquiring an additional 1,202 shares during the period. TD Asset Management Inc boosted its holdings in shares of Lantheus by 16.4% in the fourth quarter. TD Asset Management Inc now owns 94,172 shares of the medical equipment provider’s stock valued at $5,839,000 after acquiring an additional 13,280 shares in the last quarter. Finally, Olympiad Research LP acquired a new position in shares of Lantheus during the fourth quarter valued at approximately $203,000. 99.06% of the stock is owned by institutional investors.
Lantheus Price Performance
Shares of NASDAQ:LNTH opened at $107.36 on Friday. The company’s fifty day moving average is $104.45 and its two-hundred day moving average is $85.69. The company has a market cap of $7.44 billion, a P/E ratio of 16.39 and a beta of 0.50. Lantheus Holdings, Inc. has a 12-month low of $50.20 and a 12-month high of $126.89. The company has a quick ratio of 4.41, a current ratio of 4.68 and a debt-to-equity ratio of 0.55.
Analysts Set New Price Targets
A number of equities research analysts have weighed in on the company. Leerink Partners upped their target price on Lantheus from $106.00 to $127.00 and gave the stock an “outperform” rating in a research report on Thursday, July 11th. B. Riley boosted their price target on shares of Lantheus from $105.00 to $146.00 and gave the stock a “buy” rating in a research report on Thursday, July 25th. Redburn Atlantic started coverage on shares of Lantheus in a research report on Tuesday, September 3rd. They set a “buy” rating and a $175.00 price objective for the company. Truist Financial dropped their target price on shares of Lantheus from $141.00 to $135.00 and set a “buy” rating on the stock in a report on Thursday, August 1st. Finally, JMP Securities decreased their price target on shares of Lantheus from $130.00 to $125.00 and set a “market outperform” rating on the stock in a research report on Thursday, August 1st. Two investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $126.00.
Read Our Latest Analysis on Lantheus
Insider Transactions at Lantheus
In related news, President Paul Blanchfield sold 2,000 shares of the business’s stock in a transaction that occurred on Thursday, August 8th. The shares were sold at an average price of $96.39, for a total transaction of $192,780.00. Following the transaction, the president now directly owns 98,980 shares of the company’s stock, valued at $9,540,682.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, President Paul Blanchfield sold 2,000 shares of Lantheus stock in a transaction on Thursday, August 8th. The stock was sold at an average price of $96.39, for a total transaction of $192,780.00. Following the completion of the sale, the president now owns 98,980 shares of the company’s stock, valued at $9,540,682.20. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Mary Anne Heino sold 10,481 shares of the company’s stock in a transaction dated Friday, August 2nd. The stock was sold at an average price of $95.50, for a total value of $1,000,935.50. Following the completion of the transaction, the director now directly owns 454,923 shares in the company, valued at $43,445,146.50. The disclosure for this sale can be found here. Insiders sold 40,852 shares of company stock valued at $3,922,001 over the last three months. 1.50% of the stock is owned by corporate insiders.
Lantheus Company Profile
Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.
Read More
- Five stocks we like better than Lantheus
- Options Trading – Understanding Strike Price
- Can Costco Stock Hit New Highs as Interest Rates Drop?
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- These 3 Stocks Show How to Navigate Declining Consumer Confidence
- 3 Warren Buffett Stocks to Buy Now
- MicroStrategy’s Returns Are 3X Higher Than Bitcoin: Time to Buy?
Want to see what other hedge funds are holding LNTH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lantheus Holdings, Inc. (NASDAQ:LNTH – Free Report).
Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.